We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Removal of a p53 Inhibitor Causes Cancer Cell Death

By LabMedica International staff writers
Posted on 06 Jul 2009
Cancer researchers employing a novel technique to study the p53 tumor suppressor gene in normal rather than cancerous tissues have identified Trim24 as a p53 inhibitor that may be susceptible to drug treatment.

Tripartite motif-containing 24 (Trim24) also known as transcriptional intermediary factor 1-alpha (TIF1-alpha) is a protein, which in humans is encoded by the Trim24 gene. More...
The protein encoded by this gene mediates transcriptional control by interaction with the activation function-2 (AF-2) region of several nuclear receptors, including the estrogen, retinoic acid, and vitamin D3 receptors. The protein localizes to nuclear bodies and is thought to associate with chromatin and heterochromatin-associated factors.

Investigators at the University of Texas M. D. Anderson Cancer Center (Houston, USA) created a mouse and stem cell model by knock-in (KI) genetic engineering. The new line of mice had a tandem-affinity-purification (TAP) epitope linked to p53. Mass spectrometry of TAP-purified p53-complexes from embryonic stem cells revealed the presence of Trim24, a previously unknown partner of p53.

Results from additional experiments published in the June 25, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) showed that expression of p53 activity was inversely proportional to the levels of Trim24. Trim24 marked the p53 protein with ubiquitin for proteosomal destruction. Complete removal of Trim24 in human breast cancer cells caused p53-dependent, spontaneous apoptosis.

"We wanted to purify p53 from normal cells to better understand the mechanisms that regulate it," said senior author Dr. Michelle Barton, professor of biochemistry and molecular biology at University of Texas M. D. Anderson Cancer Center. "Targeting Trim24 may offer a therapeutic approach to restoring p53 and killing tumor cells."

Related Links:
University of Texas M. D. Anderson Cancer Center




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.